Cargando…

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy

Refractory hypercholesterolemia (RH), including homozygous familial hypercholesterolemia (HoFH) and compound heterozygous familial hypercholesterolemia, is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) despite existing cholesterol-lowering methods at maximal tolerable d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhi-Fan, Wu, Na-Qiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218664/ https://www.ncbi.nlm.nih.gov/pubmed/35754818 http://dx.doi.org/10.3389/fgene.2022.911429

Ejemplares similares

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

Genetics, Screening, and Treatment of Familial Hypercholesterolemia: Experience Gained From the Implementation of the Vietnam Familial Hypercholesterolemia Registry
por: Truong, Thanh-Huong, et al.
Publicado: (2020)

Genetics of Familial Hypercholesterolemia: New Insights
por: Vrablik, Michal, et al.
Publicado: (2020)

Genetic Diagnosis of Familial Hypercholesterolemia in Asia
por: Huang, Chin-Chou, et al.
Publicado: (2020)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
por: Vuorio, Alpo, et al.
Publicado: (2021)

Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia
por: Shu, Hong-Yan, et al.
Publicado: (2021)

Familial Hypercholesterolemia in Russia: Three Decades of Genetic Studies
por: Vasilyev, Vadim, et al.
Publicado: (2020)

Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia
por: Tada, Hayato, et al.
Publicado: (2022)

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
por: Vuorio, Alpo, et al.
Publicado: (2022)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021)

Analysis of Differentially Expressed Genes and Molecular Pathways in Familial Hypercholesterolemia Involved in Atherosclerosis: A Systematic and Bioinformatics Approach
por: Udhaya Kumar, S., et al.
Publicado: (2020)

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study
por: D’Erasmo, Laura, et al.
Publicado: (2022)

Familial Hypercholesterolemia Prevalence Among Ethnicities—Systematic Review and Meta-Analysis
por: Toft-Nielsen, Frida, et al.
Publicado: (2022)

The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype–Phenotype Correlations of the Disease
por: Kamar, Amina, et al.
Publicado: (2021)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Fast and Easy Nanopore Sequencing Workflow for Rapid Genetic Testing of Familial Hypercholesterolemia
por: Soufi, Muhidien, et al.
Publicado: (2022)

Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials
por: Wasnik, Vaibhavi B, et al.
Publicado: (2022)

Gene-Editing Technologies and Applications in Legumes: Progress, Evolution, and Future Prospects
por: Baloglu, Mehmet Cengiz, et al.
Publicado: (2022)

The risk of various types of cardiovascular diseases in mutation positive familial hypercholesterolemia; a review
por: Hovland, Anders, et al.
Publicado: (2022)

Low Detection Rates of Genetic FH in Cohort of Patients With Severe Hypercholesterolemia in the United Arabic Emirates
por: Rimbert, Antoine, et al.
Publicado: (2022)

Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care
por: Loh, Wann Jia, et al.
Publicado: (2022)

Early Discovery of Children With Lysosomal Acid Lipase Deficiency With the Universal Familial Hypercholesterolemia Screening Program
por: Sustar, Ursa, et al.
Publicado: (2022)

Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia
por: Oommen, Deepu, et al.
Publicado: (2020)

The Prevalence and Genetic Spectrum of Familial Hypercholesterolemia in Qatar Based on Whole Genome Sequencing of 14,000 Subjects
por: Diboun, Ilhame, et al.
Publicado: (2022)

Do Biobank Recall Studies Matter? Long-Term Follow-Up of Research Participants With Familial Hypercholesterolemia
por: Nurm, Miriam, et al.
Publicado: (2022)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
por: Stoll, Felicitas, et al.
Publicado: (2022)

Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: The ARIAN study
por: Arrobas Velilla, Teresa, et al.
Publicado: (2022)

The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group
por: Gazzotti, Marta, et al.
Publicado: (2022)

Gene therapy for lysosomal storage diseases: Current clinical trial prospects
por: Kido, Jun, et al.
Publicado: (2023)

Genetic and Clinical Characteristics of Patients With Homozygous and Compound Heterozygous Familial Hypercholesterolemia From Three Different Populations: Case Series
por: Marusic, Tatiana, et al.
Publicado: (2020)

Corrigendum: The role of registers in increasing knowledge and improving management of children and adolescents affected by familial hypercholesterolemia: The LIPIGEN pediatric group
por: Gazzotti, Marta, et al.
Publicado: (2023)

Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma
por: Zhu, Zhi-gang, et al.
Publicado: (2022)

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
por: Rosenson, Robert S., et al.
Publicado: (2023)

Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene
por: Idrees, Muhammad, et al.
Publicado: (2018)

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
por: Weintraub, Spencer F., et al.
Publicado: (2022)

Applying amplification refractory mutation system technique to detecting cell-free fetal DNA for single-gene disorders purpose
por: Tan, Yu, et al.
Publicado: (2023)

Assessment of Associations Between Serum Lipoprotein (a) Levels and Atherosclerotic Vascular Diseases in Hungarian Patients With Familial Hypercholesterolemia Using Data Mining and Machine Learning
por: Németh, Ákos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_peahq49asprnhavdt82k061qv0